Liquid Biopsies such as circulating tumour DNA (ctDNA) have emerged as a noninvasive biomarker to track tumour burden and allow real-time monitoring of the cancer genome in blood. Through recent advances in genomic technologies including next-generation sequencing, ctDNA analysis can be used across a range of malignancies to detect minimal residue disease, guide treatment selection and detect the emergence of treatment resistance. This webinar will outline the technological advances in ctDNA analysis, highlight the role of ctDNA analysis in the clinical management of cancer patients and the future potential for ctDNA analysis to impact cancer care.

The key things you will learn in this webinar are:

• Understand the technological advances in ctDNA (circulating tumour) analysis
• Highlight the role of ctDNA analysis in management of cancer patients
• Understand the future potential of ctDNA analysis in cancer care

Speaker:

Dr Stephen Wong Head of the Cancer Genomics Translational Research Centre, Peter MacCallum Cancer Centre Dr. Stephen Wong is Head of the Cancer Genomics Translational Research Centre at the Peter MacCallum Cancer Centre. He oversees the design, development and coordination of multiple translational research projects for both academic and commercial partners using a range of cutting-edge genomic-based methodologies. His research encompasses clinical oncology, computational biology and biostatistics and has led the discovery of novel cancer biomarkers and implementation of diagnostic methods into clinical practice.